USP Standard for Dissolution Testing withdrawn
Recommendation
13-15 May 2025
Vienna, Austria
Practical Approaches for USP General Chapter <1058> Compliance in the QC Laboratory
Register now for ECA's GMP Newsletter
In a notice from 20 December 2011 the United States Pharmacopeia (USP) has notified that Chlorpheniramine Maleate Extended-Release Tablets RS will be withdrawn as of 1 February 2012.
These tablets had been used for testing the Performance Verification Suitability according to the General Chapter <711> for Apparatus 3.
This withdrawal is due to the fact that no suitable replacement candidate has been found to date.
USP remains convinced that a Performance Verification Test is a critical element in the qualification of dissolution apparatuses.
During the ECA Conference "Dissolution Testing - Development - Quality Control - and in vivo Relevance" taking place from 17-19 October 2012 in Berlin, the newest USP requirements concerning the qualification of apparatuses will be presented and compared to the FDA requirements on mechanical qualification.
Please also read USP's complete notice.
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
20.03.2025EMA publishes Considerations regarding the Implementation of ICH M13A on Bioequivalence
19.03.2025WHO: Updates on Method Transfer
19.03.2025Further Modifications to USP Chapter <621> Chromatography Published for Comment
12.03.2025Proposed Update to USP <1058> on Analytical Instrument and System Qualification
06.03.2025Eurachem publishes Leaflet on Analytical Equipment and Systems
26.02.2025FDA Warning Letter Highlights Responsibilities of Contract Testing Laboratories